Metsera, Inc. (NASDAQ:MTSR - Get Free Report)'s share price traded up 13.4% on Monday . The stock traded as high as $27.12 and last traded at $27.08. 432,115 shares changed hands during trading, a decline of 50% from the average session volume of 861,302 shares. The stock had previously closed at $23.87.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. Guggenheim assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $56.00 price objective on the stock. Evercore ISI assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating on the stock. Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 price objective on the stock. Finally, Cantor Fitzgerald assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "overweight" rating on the stock.
Read Our Latest Report on MTSR
Metsera Stock Performance
The company's 50-day simple moving average is $22.86.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($1.03) EPS for the quarter.
Institutional Investors Weigh In On Metsera
A number of large investors have recently added to or reduced their stakes in MTSR. New York State Common Retirement Fund bought a new stake in Metsera in the 1st quarter worth $131,000. Corebridge Financial Inc. bought a new stake in Metsera in the 1st quarter worth $206,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Metsera in the 1st quarter worth $248,000. MetLife Investment Management LLC bought a new stake in shares of Metsera during the 1st quarter valued at about $254,000. Finally, Invesco Ltd. bought a new stake in shares of Metsera during the 1st quarter valued at about $271,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
